Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Natalizumab price?

See the DrugPatentWatch profile for Natalizumab

Natalizumab (brand name Tysabri) is a high‑cost biologic used mainly for relapsing‑remitting multiple sclerosis and Crohn’s disease. The pricing can vary depending on the country, the payer, and whether you’re buying a vial, a pre‑filled syringe, or an infusion kit. Here’s a general snapshot of what you’re likely to see:

Country Typical Cost (per infusion or annual) Notes
United States $35,000 – $40,000 per year (or about $4,500 – $5,500 per infusion) The average wholesale price (AWP) for a 300 mg vial (the usual dose) is around $8,000‑$9,000. Patients typically get 12 infusions per year, so the total AWP comes to roughly $35k‑$40k. Actual out‑of‑pocket costs are usually far lower thanks to insurance, pharmacy benefit managers, or manufacturer assistance programs.
Canada $20,000 – $25,000 per year Covered under provincial drug plans; the list price is lower than in the U.S. but varies by province.
United Kingdom £15,000 – £20,000 per year NHS procurement prices are negotiated; patients usually pay no cost if they’re on the NHS.
Australia AUD $25,000 – $30,000 per year PBS listing reduces the cost, but the patient may still pay a co‑payment.

What the numbers actually mean

  1. Average Wholesale Price (AWP)

    • AWP is a list price used for contracts and insurance negotiations. It’s often 30%‑40% higher than the actual price that patients pay.
  2. Patient‑Facing Costs

    • With commercial insurance in the U.S., most patients have a copay that ranges from $0 to $500 per infusion, depending on the plan.
    • If you’re on Medicare Part B (for those over 65 or with certain disabilities), the drug is covered after a deductible and a small co‑insurance (usually 10% of the Medicare fee schedule).
  3. Manufacturer Assistance

    • Novartis (the manufacturer) offers a Natalizumab Patient Assistance Program (PAP) for uninsured or under‑insured patients. The program can cover most, if not all, of the cost.
    • Eligibility usually requires a household income below a certain threshold and documentation of lack of insurance.
  4. Generic/Alternative Options

    • As of 2024, there are no approved generics of natalizumab. However, other disease‑modifying therapies (e.g., ocrelizumab, siponimod) are available at lower or comparable prices and may be considered if cost is a major barrier.

Tips if you’re paying out‑of‑pocket

  • Ask for a “price guarantee” from the infusion center; many centers will negotiate a lower price if you’re paying directly.
  • Check with your pharmacy: Some outpatient infusion centers can bulk‑buy the drug and pass the savings on.
  • Explore state or local assistance programs that can cover infusion costs.

Bottom line

While the list price of natalizumab sits around $35k–$40k per year in the U.S., most patients do not pay that amount. Insurance, Medicare, or manufacturer assistance typically bring the real cost down to a few hundred dollars (or even zero) per infusion. If you’re trying to figure out your exact out‑of‑pocket expense, it’s best to call your infusion center and insurance provider with your policy ID on hand.



Other Questions About Natalizumab :

Natalizumab patent expiry? Natalizumab spc? Natalizumab patent expiry eurasia ea patents? Natalizumab patent? Natalizumab cost? Ranitherapeutics natalizumab patent? When will natalizumab go off patent?